Authors

• Ljiljana Banfić — Medicinski fakultet Sveučilišta u Zagrebu, Klinički bolnički centar Zagreb, Zagreb, Hrvatska — ORCID: 0000-0002-4538-8980
• Majda Vrkić Kirhmajer — Medicinski fakultet Sveučilišta u Zagrebu, Klinički bolnički centar Zagreb, Zagreb, Hrvatska — ORCID: 0000-0002-1340-1917
• Mislav Puljević — Medicinski fakultet Sveučilišta u Zagrebu, Klinički bolnički centar Zagreb, Zagreb, Hrvatska — ORCID: 0000-0003-1477-2581
• Zoran Miovski — Medicinski fakultet Sveučilišta u Zagrebu, Klinički bolnički centar Zagreb, Zagreb, Hrvatska — ORCID: 0000-0002-3850-8905
• Krešimir Putarek — Medicinski fakultet Sveučilišta u Zagrebu, Klinički bolnički centar Zagreb, Zagreb, Hrvatska — ORCID: 0000-0003-0361-5740
• Marijan Pašalić — Medicinski fakultet Sveučilišta u Zagrebu, Klinički bolnički centar Zagreb, Zagreb, Hrvatska — ORCID: 0000-0002-3197-2190

Abstract

Registry “Deep vein thrombosis” includes and evaluates all patients with deep vein thrombosis (DVT) treated at the Department of Vascular Diseases, University Hospital Centre Zagreb from 1st January 2016. The results of the registry will be presented as compared to the results presented at the 11th Congress of Croatian Cardiology Society (1), which were related to the pilot project in the period of 1st January until 1st October 2016. The registry includes a total of 305 patients. Parameters covered by the registry relate to the etiology of venous thrombosis, disease localization, complications during treatment, treatment in the acute phase and in the advanced treatment phase. Out of the total data, we highlight an increase of the patients with venous thrombosis related by a surgical procedure (8.8%). In the total population incidence of venous thrombosis after the previous surgical procedure was 23%. The initial treatment of DVT in the acute phase (**Figure 1**) increased significantly in favor of the use of novel oral anticoagulants (NOAC) (15.5%) because in the first 10 months of the pilot project all patients were treated with low molecular weight heparin (LMWH) and warfarin, while in the past 2 years this number was reduced. In the prolonged treatment (**Figure 2**) the use of LMWH increased by 12.2%, the use of NOAC by 27.4%, while the application of the standard treatment method to warfarin recorded a decline of 39.6%. The occurrence of bleeding is reduced by 3%. FIGURE 1. Treatment options during 2016 compared with 2016-2018 in the acute phase of treatment. NOAC = novel oral anticoagulants; LMWH = low molecular weight heparin. FIGURE 2. Treatment options during 2016 compared withj 2016-2018 in the extended treatment. LMWH = low molecular weight heparin; NOAC = novel oral anticoagulants; standard th. = standard therapy. In the period of 2 years, the method of treating venous thrombosis has significantly changed in favor of treatment with new oral anticoagulants, resulting in an increase in the number of outpatient treatment by 15.5%, with a decrease in the occurrence of bleeding by 3%.

Keywords

deep vein thrombosis, registry, novel oral anticoagulants, low molecular weight heparin, warfarin

DOI

Literature

1. Puljević M, Miovski Z, Banfić L. Vrkić Kirhmajer M, Krpan M, Putarek K, Pašalić M. Croatian Registry of Patients with Deep Vein Thrombosis: A Pilot Study. Cardiol Croat. 2016;11(10-11):521. https://doi.org/10.15836/ccar2016.521